SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the ...

The biggest stories of the day delivered to your inbox.

VaporTheGamer reacts to zardy is back with phase 2 in friday night funkin'! with fun commentary, unique insights, and FNAF or FNF fan excitement. Trump discovers Maduro’s Achilles’ heel New class of ...

Fluor and JGC said Monday they had handed over LNG Canada's second production train, bringing the Shell-led project's capacity to 14 million tons a year. Image by MikeMareen via iStock Fluor Corp and ...

So you can Hades while you Hades. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

Phase 1 of S-100 Standards implementation is now complete after the operational release of standards S-124 Navigational Warnings and S-128 Catalogue of Nautical Products. The S-100 framework is a new ...

aResearch and Early Development, Novo Nordisk A/S, Måløv, Denmark bDevelopment, Novo Nordisk A/S, Søborg, Denmark ...

RG6501 (OpRegen) cell therapy shows sustained visual acuity and retinal structure improvements in GA patients over 36 months. Extensive coverage of OpRegen therapy leads to greater BCVA and retinal ...

ACE-232 is a potent CYP11A1 inhibitor showing efficacy in preclinical models resistant to current mCRPC therapies. The phase 1 trial will enroll 67 patients to evaluate safety, tolerability, and ...